Use of rifabutin in combination with atovaquone, clindamycin, pyrimethamine, or sulfadiazine for treatment of toxoplasmic encephalitis in mice

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 15, Issue 5, 1996, Pages 394-397

  Araujo, F G ^a   Suzuki, Y ^a,b   Remington, J S ^a,b  

^a PALO ALTO MEDICAL FOUNDATION   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ATOVAQUONE; CLINDAMYCIN; PYRIMETHAMINE; RIFABUTIN; SULFADIAZINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; ENCEPHALITIS; FEMALE; HISTOPATHOLOGY; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SIDE EFFECT; TOXOPLASMOSIS;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTIPROTOZOAL AGENTS; ATOVAQUONE; BRAIN; CLINDAMYCIN; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ENCEPHALITIS; FEMALE; MICE; MICE, INBRED CBA; NAPHTHOQUINONES; PYRIMETHAMINE; RIFABUTIN; SULFADIAZINE; TOXOPLASMOSIS, CEREBRAL; TREATMENT OUTCOME;

EID: 0029898350     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01690096     Document Type: Article

References (11)

1. Wong SY, Remington JS: Biology of Toxoplasma gondii. AIDS 1993, 7: 299-316.
2. Luft BJ, Remington JS: Toxoplasmic encephalitis in AIDS. Clinical Infectious Diseases 1992, 15: 211-222.
3. Israelski DM, Remington JS: Toxoplasmic encephalitis in patients with AIDS. Infectious Disease Clinics of North America 1988, 2: 429-445.
4. Wong SY, Remington JS: Toxoplasmosis in the setting of AIDS. In: Broder S, Merigan TC, Bolognesi D (ed): Textbook of AIDS medicine. Williams and Wilkins, Baltimore, 1994, p. 223-257.
5. Wong SY, Israelski DM, Remington JS: AIDS associated toxoplasmosis. In: Sande MA, Volberding P (ed): The medical management of AIDS. W.B. Saunders, Philadelphia, 1995, p. 460-493.
6. Araujo FG, Remington JS: Recent advances in the search for new drugs for treatment of toxoplasmosis. International Journal of Antimicrobial Agents 1992, 1: 153-164.
7. Araujo FG, Slifer T, Remington JS: Rifabutin is active in models of murine toxoplasmosis. Antimicrobial Agents and Chemotherapy 1994, 38: 570-575.
8. Araujo FG, Huskinson-Mark J, Gutteridge WE, Remington JS: In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii. Antimicrobial Agents and Chemotherapy 1992, 36: 326-330.
9. Israelski DM, Araujo FG, Conley FK, Suzuki Y, Remington JS: Treatment with anti-L3T4 (CD4) monoclonal antibody reduces the inflammatory response in toxoplasmic encephalitis. Journal of Immunology 1989, 142: 954-958.
10. O'Brien RJ, Lyle MA, Snider DEJ: Rifabutin (ansamycin LM427): a new rifamycin-S derivative for the treatment of mycobacterial diseases. Reviews of Infectious Diseases 1987, 9: 519-530.
11. Gutteridge WE: New antiprotozoal agents. International Journal of Parasitology 1987, 17: 121-130.